The Geneva-based biotech startup is developing an innovative therapeutic approach to treat neurological and psychiatric disorders by targeting glial cells. With the success of its pre-clinical studies, the company is planning to launch the clinical phase next year. The receipt of the Innosuisse Certificate further affirms GliaPharm’s maturity.
![[Campus Biotech] GliaPharm braces to enter the clinical phase](https://republic-of-innovation.ch/wordpress/wp-content/uploads/2022/03/GliaPharm_Cofounders-630x276.png)